Pyxis Oncology, Inc. Common Stock

PYXSNASDAQ • USD
1.41 USD
↘ 0.01 (0.36%)🟢LIVE (AS OF 02:26 PM EST)
🟢Market: OPEN

Pyxis Oncology, Inc. Common Stock (PYXS) is currently trading at $1.41. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On the valuation front, PYXS trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Nov 16, 2026.

Open?$1.48
High?$1.55
Low?$1.36
Prev. Close?$1.41
Volume?1.1M
Avg. Volume?837.2K
VWAP?$1.40
Rel. Volume?1.30x
Bid / Ask
Bid?$1.40 × 700
Ask?$1.41 × 1.0K
Spread?$0.01
Midpoint?$1.40
Valuation & Ratios
Market Cap?168.6M
Shares Out?119.6M
Float?93.5M
Float %?78.2%
P/E Ratio?N/A
P/B Ratio?4.08
EPS?-$0.72
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
Employees
56
Market Cap
189.0M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2021-10-08
Address
321 HARRISON AVENUE
BOSTON, MA 02118
Phone: (617) 221-9059
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
49
Piotroski F-Score?0/9Weak
Altman Z-Score?-9.56Distress
Confidence?54%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?4.84%Low
Short Interest?4.5M
Days to Cover?5.8
Free Float93.5M
Avg Daily Volume777.6K
Settlement Date2026-10-30
Financial Health
Current Ratio?2.96Strong
Quick Ratio?2.96Strong
Cash Ratio?0.19Low
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
44
4.08FAIR▾
P/S?
Peers
100
S&P
3
15.28HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.9CHEAP▾
EV/Sales?
Peers
100
S&P
3
14.93HIGH▾
Returns & Efficiency
ROE?
S&P
3
-209.9%WEAK▾
ROA?
S&P
3
-112.9%WEAK▾
Cash Flow & Enterprise
FCF?$-70927000
Enterprise Value?$164.8M
Fundamentals ratios updated end of day